• Adapting blood sterilization technology to manufacture metabolically active, nonreplicating tumor cells for autologous immunotherapy to simplify production and preserve immunogenic function

• Manufacturing workflow from tumor resection to reinjection – streamlining critical steps to reduce turnaround time and improve reproducibility

• Advancing toward clinical translation in relapsed ovarian cancer to demonstrate realworld applicability and pave the way for broader tumor indications